Abstract

HTA143 Drug Market Access Delays in France: What Role May Cost-Effectiveness Evaluations Play in Varying These Timescales?

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call